Introduction
Breast cancer is the most diagnosed female cancer and the fifth leading cause of cancer death, and the mortality rate is 70,700 patients every year in China. 1 The incidence and mortality of this cancer in women is increasing in recent years. 1 Classical therapeutic strategy for this disease in clinic is combining the loco-regional therapy (surgery and radiation) with subsequent adjuvant systemic therapy. [2] [3] [4] However, as a highly heterogeneous disease, the therapeutic effect of breast cancer is determined by various classical clinical phenotypes (age at diagnosis, tumor size, stage of tumor, lymph node invasiveness, etc.) as well as intrinsic molecular subtypes (triple negative, human epidermal growth factor receptor 2 [HER2]-enriched, luminal A and luminal B subtypes). 2, 5 Besides, in the era of personalized medicine, genetic factors get increasing attention, which are considered as the most important aspects in tumor initiation, progression, prognosis, and drug resistance. 4, 6 Therefore, accurate molecular diagnosis of specific biomarkers that can respond to and monitor the therapeutic effect of breast cancer is essential.
As a major component of PI3K/AKT/mTOR signaling pathway, the activation of phosphatidylinositol-3 kinases (PI3K) which interacts with transmembrane tyrosine-kinase growth factor receptors subsequently activates AKT, mTOR, MAPK signaling pathways, and plays essential roles in multiple cellular processes including translation regulation, protein synthesis, cell metabolism, autophagy, cell adhesion, and apoptosis. 7, 8 Numerous studies illustrated that hyperactivation of PI3K signaling intimately was associated with pathogenesis and progression of various types of cancers. [9] [10] [11] [12] [13] There are two most important events that could constitutively activate the PI3K signaling pathway -loss of the function of tumor suppressor phosphate and tension homology deleted on chromosome ten (PTEN) and activation mutations in p110α catalytic subunit which encoded by the PIK3CA gene. 8, 14 Between them, PIK3CA is one of the most prevalent mutated genes in breast cancer even though its mutation frequency varies among different investigations. [15] [16] [17] [18] [19] According to the Catalogue of Somatic Mutations in Cancer Database (COSMIC, https://www.sanger.ac.uk), >90% of the PIK3CA mutations are located in the helical (exon 9) or kinase (exon 20) domains, including the hotspot mutations E542K, E545K in exon 9 and H1047R, H1047L in exon 20.
Therefore, multiple studies have been performed to investigate the relationship between PIK3CA mutations and clinicopathological features, prognostic value, or therapeutic relevance of breast cancer in different countries and races. 15, [20] [21] [22] However, the results are controversial among these different studies even those from the same country. For example, in two investigations in the patients from Italy, Buttitta et al 23 showed that PIK3CA mutations were associated with HER2-negative clinicopathological subtype, and in contrast, no association was determined by Barbareschi et al. 24 Harlé et al 25 attempted to correlate the PIK3CA mutations with low-grade tumors in breast cancer patients from Nancy, France, while by investigating the patients from Saint-Cloud, France, Cizkova et al 26 believed that there were correlations between PIK3CA mutations and estrogen receptor (ER)-positive, progesterone receptor (PR)-positive, HER2 negative, low tumor grade or small tumor size. Considering the small sample sizes, population-related peculiarities of patients, and different methods used for detection of the mutations, these phenomena might demonstrate that it is crucially important to analyze carefully these factors in more areas including a larger population with a unique method. The outcomes would help us to deeply understand breast cancer and offer us specific and predictive biomarkers to be used for breast cancer diagnosis and treatment.
In this study, we investigated the frequency, distribution, bias, and burden of PIK3CA mutations in 494 breast cancer patients from a single center located in Central China and explored their associations with clinicopathological features and disease prognosis. These data will expand the knowledge of PIK3CA mutations related to breast cancer, which can be further used to provide precision medicine strategies to the breast cancer patients in Central China.
Materials and methods Patients
The study was conducted in accordance with the Declaration of Helsinki. After obtaining written informed consent from all the patients and approval of the Ethics Committee of the First Affiliated Hospital of USTC, 537 formalin-fixed, paraffinembedded (FFPE) primary breast tumor tissue samples were collected at the Department of Pathology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China from 2010 to 2017. Ultimately, 494 samples were eligible for our analysis and the clinical characteristics of these patients are summarized in Table S1 . All the samples were obtained from female patients who did not receive preoperative treatment. Based on the American Joint Committee on Cancer TNM system (2010), 27 the pathological diagnosis of each sample was made by at least three pathologists. The Nottingham Prognostic Index (NPI) 28 was calculated to determine the prognosis of the patients after surgery using the following formula: NPI =0.2×tumor size (cm)+ grade (1-3)+ lymph node status (1-3). Progression-free survival (PFS) was defined as the time span between surgery date and the first relapse time of tumor, second primary tumor, death, or last follow-up. 29 Among 494 patients, 303 PFS and overall survival (OS) data were collected in which 28 of them had relapsed tumor or second primary tumor and 46 patients died. The follow-up period was from 5 to 97 months with a median time of 35 months. 
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Wu et al considered positive when complete or intense membrane staining was determined in >30% of tumor cells. The subtypes of samples were classified using anatomopathological classification according to St. Gallen International Expert Consensus. 30 The expression of Ki67 -a cellular marker for proliferation -was also examined by IHC in all patients.
Dna preparation and targeted next generation sequencing
Tumor content of >50% was qualified through H&E staining and selected for DNA extraction. Genomic DNA was extracted from one 10 µm section using the GeneRead DNA FFPE Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The quantity and quality of extracted DNA were determined using Nanodrop spectrophotometer 2000 (Thermo Fisher Scientific, MA, USA) and Qubit 3.0 (Life Technologies, Carlsbad, CA, USA).
Genetic variants of 24 samples were screened with TruSeq Amplicon Cancer Panel (Illumina, San Diego, CA, USA) using the NextSeq 500 sequencing system (Illumina). Mutations in 212 amplicons from 48 genes were examined in these samples, including BRAF, KRAS, EGFR, TP53, NRAS, ALK, IDH1, FGFR, PTEN, RB, ATM, PIK3CA, and other important cancer-related genes. Among them, the total 20 exons of PIK3CA were targeted.
After sequencing, mapping, and alignment, single nucleotide variants (SNVs) and indels were called and annotated based on the method described by The Cancer Genome Altas. 31 Variants with insufficient coverage (minimum depth of coverage <8) and low variant allele frequency (<0.03) were filtered out.
PCR amplification of the PIK3CA exon 9 and exon 20 fragments
The exon 9 and exon 20 of PIK3CA gene were amplified using the following primers: exon 9 forward 5′-TGTAAAACGACG-GCCAGTCAGAGTAACAGACTAGCTAGAGACAATG-3′, exon 9 reverse 5′-CAGGAAACAGCTATGACCAATCTC-CATTTTAGCACTTACCTGTGAC-3′, and exon 20 forward 5′-TGAGCAAGAGGCTTTGGAGTAT-3′, exon 20 reverse 5′-CCTATGCAATCGGTCTTTGC-3′. The PCR was performed in a 20 µL reaction system using FastStart Essential DNA Green Master Kit (Roche, Mannheim, Germany) with 1 µL gDNA, 1 µL forward primer (10 nmol/mL), 1 µL reverse primer (10 nmol/mL), and 10 µL FastStart Essential DNA Green Master. The PCR was carried out on a LightCycler 96 Real-Time PCR System (Roche) under the following conditions: initial denaturation at 95°C for 5 minutes, then 45 cycles of 95°C for 20 seconds, 60°C for 30 seconds, and 72°C for 30seconds.
Detection of PIK3CA mutations by sanger sequencing
For sequence analysis, PCR products were purified by PCR Product Purification Kit (Generalbiol, Anhui, China) and subjected to bidirectional dye-terminator sequencing using M13 forward primer 5′-TGTAAAACGACGGCCAGT-3′ for exon 9 amplicon and exon 20 reverse primer 5′-CCTATG-CAATCGGTCTTTGC-3′ for exon 20 amplicon. Sequencing fragments were detected by capillary electrophoresis using the ABI 3730xl DNA analyzer (Applied Biosystems, Carlsbad, CA, USA) and then analyzed by SnapGene Viewer 4.2.6. The mutations were identified by manual review.
statistical analysis
The relations between PIK3CA mutation statuses and clinicopathological characteristics were assessed by the Pearson chisquared tests using SPSS software v19.0.0 (IBM, NY, USA). The HR of PIK3CA mutation as well as clinicopathological variables was calculated by the Cox proportional hazards regression model in univariate analysis. Based on the PFS in different mutation conditions, the Kaplan-Meier survival curves were drawn using GraphPad Prism software v5.01 (GraphPad, San Diego, CA, USA) and the significant differences were displayed by the log-rank test (SPSS v 19.0.0, IBM). Statistical significance was considered as P<0.05.
Results

somatic mutations in breast cancer patients from Central China
To investigate the somatic mutations in breast cancer, 24 primary tumor samples were analyzed using targeted next generation sequencing (NGS). A mean coverage depth of 8,525× was achieved. 94.4% of amplicons were covered at >500× depth. After SNV and indel calling, a total of 93 mutations were detected, including 27 synonymous SNVs, 48 nonsynonymous SNVs, 3 stopgains, 3 splicings, 10 frameshift deletions, 1 nonframeshift deletion, and 1 frameshift insertion. The overall mutation frequency was 2.75 nonsilent mutations (range of 0-12 mutations) per sample. As shown in Figure 1 , the most frequently mutated gene was TP53 (41.7%, 10 of the 24 patients) with various mutation types (missense mutation, nonsense mutation, frameshift insertion, and splicing). PIK3CA mutation was found in 33% of the samples, which ranked as the second highest mutated gene. All of the PIK3CA mutations were 
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Wu et al hotspot mutations including three E542K, three E545K, and two H1047R (Table S2 ). This much higher mutation rate in PIK3CA exon 9 (75%) in breast cancer was quite different from previous reports 19, [32] [33] [34] which attracted our attention. Besides, we examined the clinicopathological variables of these patients and found that the samples harbored exon 9 mutations were HER2-negative tumors and all belonged to luminal B molecular subtype (Table  S2) . Furthermore, the only two tumor-relapsed cases were also from the group with exon 9 mutations, which demonstrated that exon 9 mutations might be related to poor prognosis (Table S2) . Therefore, we hypothesized that the proportion of PIK3CA exon 9 mutations was much higher in the female breast cancer patients from our area (Central China) than the other regions, and this preference was correlated with special clinicopathological characteristics and tumor prognosis.
PIK3CA mutations detection in archival FFPe tissues
To verify our hypothesis, the mutations in exon 9 and exon 20 of PIK3CA gene were examined by direct sequencing in 537 primary breast tumor samples including the 24 specimens analyzed by NGS to validate the results of sequencing. Among the succeeded sequenced 494 (92%) samples, PIK3CA mutations were determined in 188 (38%) tumors, including 74 mutations in exon 9, 106 mutations in exon 20, and 8 in both exons 9 and 20 ( Table 1 ). The hotspot mutations accounted for 74.6% of total mutations (153/205) in which E542K (p.542), E545K (p.545), and H1047R/L (p.1047) were found in 28, 34, and 91 patients, respectively, with p.1047 ranking the highest (Table 1) . Seventeen patients carried two mutations and two of them had H1047R simultaneous with E542K or E545K, which had never been reported before (Table 1) . Meanwhile, we characterized 52 non-hotspot Figure 1 Somatic mutations of 24 significant mutated genes in 24 breast cancer patients. Notes: The figure shows an overview of genomic alterations (right legend) in particular genes (rows) affecting individual samples (columns). The missense mutation, nonsense mutation, frame shift insertion, frame shift deletion, in frame deletion, splice site mutation, and multiple mutation are shown as green, red, purple, blue, brown, yellow, and black, respectively. left legend denotes the percentage of mutations in 24 breast cancer samples and right plot represents the total number of mutations for each gene. 
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In addition, we found 14 new PIK3CA mutations in exon 9 and 20 in breast cancers, which have not been reported by COSMIC. Among the newly found mutations, 8 of 
them were located in exon 9, 4 in exon 20, and the other 2 in both exon 9 and 20 (Table S3 ). Whether they have any clinical significance needs to be studied further. Thus, these new mutations were not taken for the following analyses in this study. 
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As shown in Table 2 , PIK3CA mutations were positively associated with ER-positive (P=0.016), PR-positive (P=0.007), and low Ki67 labeling index (P=0.001) tumors. Meanwhile, they were negatively correlated with triple-negative breast cancer subtype (P=0.003), but were not associated with age at diagnosis, tumor stage, lymph node status, tumor size, or HER2 status. We further investigated the relationships between clinicopathological features and PIK3CA mutation distributions, including the exon 9/20 and hotspot mutations (p.542/545 and p.1047; Table 2 ). ER and PR positive were also significantly correlated with mutations in exon 9 and at p.542/545. Besides, the low Ki67 index was found in patients with exon 20 and p.1047 mutations. Meanwhile, triple-negative breast cancer patients had much less p.1047 mutations (P=0.012). In addition, p.1047 mutations were significantly associated with old diagnosis age (≥40 years old; P=0.043).
Compared to breast cancers with PIK3CA hotspot mutations, cancers carrying non-hotspot mutations were more likely to belong to triple-negative subtype (P=0.006) and be larger in tumor size (Table 2) . When analyzed by mutation burden, cancers with two mutations were more likely to be larger in tumor size compared with cancers harbored only one mutation ( Table 2) .
associations of PIK3CA gene mutations with prognosis
As shown in Table 2 , when we predicted the prognosis of the patients using the NPI method, no significant association was observed between various PIK3CA mutation statuses and prognosis.
Furthermore, prognosis analysis was conducted among 303 breast cancer patients with a median follow-up of 35 months. The Cox proportional hazards model and the Kaplan-Meier survival curve were used to evaluate the correlation between PFS rate or OS rate of breast cancer patients and PIK3CA mutation statuses.
In the univariate analysis, patients with old prognostic age (P=0.034) and small tumor size (P=0.033) exhibited better PFS, while old prognostic age (P=0.025) also correlated with better OS (Table 3) (Table 3) .
When examined by Kaplan-Meier estimate and log-rank test, the PFS of total patients with PIK3CA mutations was almost the same as wild-type patients, while the OS was significantly better in the total patients with PIK3CA mutations ( Figure 2 ). However, there were no differences in PFS/ OS between mutation and wild-type groups when examined by exon 9, exon 20, and hotspot mutations p.542/545 and p.1047 ( Figures S1 and S2) . Besides, PIK3CA mutations significantly improved the OS of the patients with old diagnosis age, low Ki67 labeling index, or luminal/HER2-enriched subtypes (Figure 3 ). Also as better prognostic effectors, exon 20 mutations as well as the hotspot p.1047 mutations were significantly associated with the PFS of the patients in HER2-negative or low Ki67 labeling index subgroups ( Figure 4 ) and the OS of the patients diagnosed as luminal/ HER2-enriched subtypes ( Figure 3 ). In contrast, exon 9 mutations and its hotspot p.542/545 mutations were found in the patients with worse PFS, who belonged to PR-positive or lymph node-negative subgroups ( Figure 4) .
When performing the univariate Cox analysis according to different clinicopathological parameters, a significant difference in PFS was observed between prognosis and exon 9 as well as p.542/545 hotspot mutations in PR-positive or lymph node-negative subgroups, exon 20 in HER2-negative or low Ki67 labeling index subgroups (Table 4) . In OS, a significantly better prognosis was found in total PIK3CA and exon 20 mutations patients with luminal/HER2-enriched subtypes, while total PIK3CA mutations patients with old diagnostic age had a better OS as well (Table 4) . These results were partially in accordance with the Kaplan-Meier analysis. Besides, no significance was detected between prognosis and PIK3CA mutation distribution/bias/burden under multiple other clinical, pathological, and molecular subtypes (Table S4) .
Discussion
To study the clinicopathological and prognostic values of PIK3CA variants in the breast cancer patients from Central China, 494 patients were investigated, and new insight into the complexity of PIK3CA mutations was provided in this research. In general, the mutation frequency (38%) in this study is relatively high as most investigations reported ~30% mutation rate using the similar detection method (Table 5) . 21, 24, 26, [35] [36] [37] [38] [39] [40] [41] [42] Interestingly, the frequency rates of PIK3CA mutations fluctuated among the studies which had been done by different groups from distinct areas of China (Table S5) . [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] This might be partially due to the sensitivity of assay methods. However, considering the controversial 
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results from the researches around the world as well as environmental factors and lifestyles playing roles in breast cancer, we hypothesized that PIK3CA mutations and its associated factors might show diversity roles among the populations from different regions. Then, we identif ied a signif icant association of PIK3CA mutations with clinicopathological and molecular characteristics, such as luminal/HER2-enriched subtypes, ER-positive, PR-positive, and low Ki67 labeling index which were partly consistent with the literature. 26, 35, 36, 40, 41, 44, 45, 47 When we separately analyzed the mutations in exon 9 and exon 20, their differences on the relationships with the clinicopathological characteristics were identified and should be considered separately when used for disease monitoring, therapeutic effect evaluation, and prognosis prediction. Besides, the point mutation p.1047, non-hotspot mutations, and more mutation burdens related to specific clinical and biological features of breast cancer might play particular roles and need to be investigated in future.
Numerous investigators reported that PIK3CA mutations are associated with prognosis. 24, 26, [39] [40] [41] 43, 44 However, this association varies and even contradict among studies. Some of them showed better prognosis of the patients with PIK3CA mutations, 24, 26, 40 and others believed worse outcome, 39, 43, 44, 50 while many researchers did not find any prognostic significance. 35, 36, 38, 49 In our study, interesting outcomes were explored when we tested the prognostic value of each PIK3CA mutation status in the subgroups separated according to different clinicopathological parameters. Firstly, total PIK3CA mutations exhibited disparate roles between FPS and OS in subgroups (Figures 2 and 3) . Secondly, both exon 9 and exon 20 mutations correlated with FPS, but in diverse subgroups (Figure 4) . Thirdly, only the effect of exon 20 mutations on the OS was identified ( Figure 3D ). Furthermore, exon 9 and exon 20 mutations revealed completely converse roles in the prognosis ( Figures 3D and 4) . Moreover, the hotspot mutations were in perfect accord with their exons ( Figures 3D, E and 4) . These results demonstrated that the variant status of PIK3CA mutations played different roles in the prognosis of breast cancer patients in our area. 
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In addition, when checking our samples, we realized that 60% of tumors in our study belonged to luminal B molecular subtype, which was extremely higher than the ratio in the other studies (~30%). This phenomenon also demonstrated that breast cancer patients in our area might have some specific preferences in genetic and clinicopathological features. However, the reasons and mechanisms need to be elucidated in future.
Limitations
This study still has some limitations. Firstly, all the samples were from a single center with a relatively small sample size. Although we identified some rules in the clinicopathological features, prognostic relevance, and PIK3CA mutation preferences, the sample size in the subgroups (stage I tumors, tumors with two mutations, and the relapsed patients) was quite small which made the results not that solid. Secondly, the followup times for most patients were too short. As >80% of breast cancer patients survive for >5 years after diagnosis, longer follow-up time is needed. Moreover, the effect and association of adjuvant systemic therapy with PIK3CA mutation status were not evaluated in this study, which might influence the progression-free/overall survival rate. Furthermore, the oncogenetic mutations in other exons were not examined, which might contribute to the prognosis of the patients.
Conclusion
PIK3CA mutations were detected using Sanger sequencing combined with targeted NGS in 38% of breast cancer patients from a single hospital in Central China. Different from the other studies, 60% of breast cancer patients were diagnosed with luminal B tumors. PIK3CA mutations were associated with ER-positive, PR-positive, low Ki67 labeling index, and luminal/HER2-enriched subtypes, while exon 9, exon 20, hotspot mutations, and mutation burdens made distinct contributions. In addition, p.1047 mutations were significantly associated with older diagnosis age. Significant heterogeneity was identified in the univariable effect of PIK3CA mutation status on FPS and OS. PIK3CA mutations patients had a better OS, which was also showed in the older diagnostic age, PR-negative, low Ki67 labeling index, and luminal/HER2-enriched subgroups. As better prognostic markers, exon 20 and p.1047 hotspot mutations significantly persisted in the HER2-negative and low Ki67 labeling index subgroups (analyzed by FPS) as well as luminal/HER2-enriched subgroup (analyzed by OS). In contrast, exon 9 and p.542/545 hotspot mutations exhibited worse prognostic factors in PR-positive and lymph node-negative subgroups when assayed using FPS. Therefore, these results demonstrated that the mutation frequency, distribution, bias, and burden of PIK3CA were related to different clincopathological characteristics, prognosis, and might play different roles in breast cancer from Central China. These differences and relationships should be deeply studied and taken into consideration during disease management. 
